tiprankstipranks
Argenx Se (ARGX)
NASDAQ:ARGX
US Market
Want to see ARGX full AI Analyst Report?

Argenx Se (ARGX) Stock Forecast & Price Target

789 Followers
See the Price Targets and Ratings of:

ARGX Analyst Ratings

Strong Buy
19Ratings
Strong Buy
17 Buy
2 Hold
0 Sell
Based on 19 analysts giving stock ratings to
Argenx
Se
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ARGX Stock 12 Month Forecast

Average Price Target

$1,038.75
▲(22.34% Upside)
Based on 19 Wall Street analysts offering 12 month price targets for Argenx Se in the last 3 months. The average price target is $1,038.75 with a high forecast of $1,247.00 and a low forecast of $850.00. The average price target represents a 22.34% change from the last price of $849.04.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"541":"$541","1248":"$1,248","717.75":"$717.8","894.5":"$894.5","1071.25":"$1,071.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1247,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.25K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1038.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.04K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":850,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$850.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[541,717.75,894.5,1071.25,1248],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,743.12,781.88,820.64,859.4,898.16,936.92,975.6800000000001,1014.44,1053.2,1091.96,1130.72,1169.48,1208.24,{"y":1247,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,743.12,765.8607692307693,788.6015384615384,811.3423076923077,834.083076923077,856.8238461538461,879.5646153846154,902.3053846153846,925.0461538461539,947.7869230769231,970.5276923076923,993.2684615384616,1016.0092307692307,{"y":1038.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,743.12,751.3415384615384,759.5630769230769,767.7846153846153,776.0061538461539,784.2276923076923,792.4492307692308,800.6707692307692,808.8923076923077,817.1138461538461,825.3353846153846,833.5569230769231,841.7784615384616,{"y":850,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":567.09,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":639.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":584.605,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":542.47,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":673.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":706.41,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":767.33,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":818.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":894.9,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":840.95,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":835.68,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":756.76,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":743.12,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$1,247Average Price Target$1,039Lowest Price Target$850.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wedbush
$1,000
Buy
17.78%
Upside
Reiterated
04/23/26
Analysts Offer Insights on Healthcare Companies: Argenx Se (NASDAQ: ARGX) and Regeneron (NASDAQ: REGN)
Citi
$1,091$1,152
Buy
35.68%
Upside
Reiterated
04/23/26
Citi Sticks to Its Buy Rating for Argenx Se (ARGX)
TD Cowen Analyst forecast on ARGX
TD Cowen
TD Cowen
$1,146
Buy
34.98%
Upside
Reiterated
04/14/26
Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK), Argenx Se (NASDAQ: ARGX) and Sight Sciences (NASDAQ: SGHT)
Bank of America Securities Analyst forecast on ARGX
Bank of America Securities
Bank of America Securities
Buy
Reiterated
04/14/26
Analysts Are Bullish on Top Healthcare Stocks: Opus Genetics (IRD), Argenx Se (ARGX)
RBC Capital Analyst forecast on ARGX
RBC Capital
RBC Capital
$890
Buy
4.82%
Upside
Reiterated
04/07/26
RBC Capital Reaffirms Their Buy Rating on Argenx Se (ARGX)
Oppenheimer Analyst forecast on ARGX
Oppenheimer
Oppenheimer
$1,060$1,014
Buy
19.43%
Upside
Assigned
04/02/26
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (NYSE: TEVA), Nuvation Bio (NYSE: NUVB) and Argenx Se (NASDAQ: ARGX)
Wells Fargo Analyst forecast on ARGX
Wells Fargo
Wells Fargo
$1,500$1,247
Buy
46.87%
Upside
Reiterated
04/01/26
Argenx Se (ARGX) Gets a Buy from Wells Fargo
UBS
$850
Hold
0.11%
Upside
Reiterated
04/01/26
UBS Keeps Their Hold Rating on Argenx Se (ARGX)
H.C. Wainwright Analyst forecast on ARGX
H.C. Wainwright
H.C. Wainwright
$940
Buy
10.71%
Upside
Reiterated
03/02/26
Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), Indivior (INDV)
Jefferies Analyst forecast on ARGX
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$1,008
Buy
18.72%
Upside
Reiterated
02/27/26
Jefferies Remains a Buy on Argenx Se (ARGX)
Piper Sandler Analyst forecast on ARGX
Piper Sandler
Piper Sandler
$1,075
Buy
26.61%
Upside
Reiterated
02/27/26
Argenx Se (ARGX) Gets a Buy from Piper Sandler
Citizens JMP Analyst forecast on ARGX
Citizens JMP
Citizens JMP
$925$944
Buy
11.18%
Upside
Reiterated
02/27/26
Argenx price target raised to $944 from $925 at CitizensArgenx price target raised to $944 from $925 at Citizens
Truist Financial Analyst forecast on ARGX
Truist Financial
Truist Financial
Buy
Reiterated
02/27/26
Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), Neurogene (NGNE)
Morgan Stanley Analyst forecast on ARGX
Morgan Stanley
Morgan Stanley
$1,160$1,230
Buy
44.87%
Upside
Reiterated
02/27/26
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (NASDAQ: TRDA), Kymera Therapeutics (NASDAQ: KYMR) and Argenx Se (NASDAQ: ARGX)
Robert W. Baird Analyst forecast on ARGX
Robert W. Baird
Robert W. Baird
$858$867
Hold
2.12%
Upside
Reiterated
02/27/26
Argenx price target raised to $867 from $858 at BairdArgenx price target raised to $867 from $858 at Baird
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wedbush
$1,000
Buy
17.78%
Upside
Reiterated
04/23/26
Analysts Offer Insights on Healthcare Companies: Argenx Se (NASDAQ: ARGX) and Regeneron (NASDAQ: REGN)
Citi
$1,091$1,152
Buy
35.68%
Upside
Reiterated
04/23/26
Citi Sticks to Its Buy Rating for Argenx Se (ARGX)
TD Cowen Analyst forecast on ARGX
TD Cowen
TD Cowen
$1,146
Buy
34.98%
Upside
Reiterated
04/14/26
Analysts Offer Insights on Healthcare Companies: Cytokinetics (NASDAQ: CYTK), Argenx Se (NASDAQ: ARGX) and Sight Sciences (NASDAQ: SGHT)
Bank of America Securities Analyst forecast on ARGX
Bank of America Securities
Bank of America Securities
Buy
Reiterated
04/14/26
Analysts Are Bullish on Top Healthcare Stocks: Opus Genetics (IRD), Argenx Se (ARGX)
RBC Capital Analyst forecast on ARGX
RBC Capital
RBC Capital
$890
Buy
4.82%
Upside
Reiterated
04/07/26
RBC Capital Reaffirms Their Buy Rating on Argenx Se (ARGX)
Oppenheimer Analyst forecast on ARGX
Oppenheimer
Oppenheimer
$1,060$1,014
Buy
19.43%
Upside
Assigned
04/02/26
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (NYSE: TEVA), Nuvation Bio (NYSE: NUVB) and Argenx Se (NASDAQ: ARGX)
Wells Fargo Analyst forecast on ARGX
Wells Fargo
Wells Fargo
$1,500$1,247
Buy
46.87%
Upside
Reiterated
04/01/26
Argenx Se (ARGX) Gets a Buy from Wells Fargo
UBS
$850
Hold
0.11%
Upside
Reiterated
04/01/26
UBS Keeps Their Hold Rating on Argenx Se (ARGX)
H.C. Wainwright Analyst forecast on ARGX
H.C. Wainwright
H.C. Wainwright
$940
Buy
10.71%
Upside
Reiterated
03/02/26
Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), Indivior (INDV)
Jefferies Analyst forecast on ARGX
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$1,008
Buy
18.72%
Upside
Reiterated
02/27/26
Jefferies Remains a Buy on Argenx Se (ARGX)
Piper Sandler Analyst forecast on ARGX
Piper Sandler
Piper Sandler
$1,075
Buy
26.61%
Upside
Reiterated
02/27/26
Argenx Se (ARGX) Gets a Buy from Piper Sandler
Citizens JMP Analyst forecast on ARGX
Citizens JMP
Citizens JMP
$925$944
Buy
11.18%
Upside
Reiterated
02/27/26
Argenx price target raised to $944 from $925 at CitizensArgenx price target raised to $944 from $925 at Citizens
Truist Financial Analyst forecast on ARGX
Truist Financial
Truist Financial
Buy
Reiterated
02/27/26
Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), Neurogene (NGNE)
Morgan Stanley Analyst forecast on ARGX
Morgan Stanley
Morgan Stanley
$1,160$1,230
Buy
44.87%
Upside
Reiterated
02/27/26
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (NASDAQ: TRDA), Kymera Therapeutics (NASDAQ: KYMR) and Argenx Se (NASDAQ: ARGX)
Robert W. Baird Analyst forecast on ARGX
Robert W. Baird
Robert W. Baird
$858$867
Hold
2.12%
Upside
Reiterated
02/27/26
Argenx price target raised to $867 from $858 at BairdArgenx price target raised to $867 from $858 at Baird
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Argenx Se

3 Months
xxx
Success Rate
14/18 ratings generated profit
78%
Average Return
+6.82%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +6.82% per trade.
1 Year
Thomas SmithLeerink Partners
Success Rate
25/27 ratings generated profit
93%
Average Return
+30.56%
Copying Thomas Smith's trades and holding each position for 1 Year would result in 92.59% of your transactions generating a profit, with an average return of +30.56% per trade.
2 Years
xxx
Success Rate
27/27 ratings generated profit
100%
Average Return
+60.34%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +60.34% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ARGX Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
0
2
5
6
5
Buy
37
37
44
33
23
Hold
4
5
5
3
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
41
44
54
42
31
In the current month, ARGX has received 28 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. ARGX average Analyst price target in the past 3 months is 1,038.75.
Each month's total comprises the sum of three months' worth of ratings.

ARGX Financial Forecast

ARGX Earnings Forecast

Next quarter’s earnings estimate for ARGX is $5.43 with a range of $2.57 to $7.18. The previous quarter’s EPS was $8.02. ARGX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ARGX has Performed in-line its overall industry.
Next quarter’s earnings estimate for ARGX is $5.43 with a range of $2.57 to $7.18. The previous quarter’s EPS was $8.02. ARGX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ARGX has Performed in-line its overall industry.

ARGX Sales Forecast

Next quarter’s sales forecast for ARGX is $1.32B with a range of $1.15B to $1.38B. The previous quarter’s sales results were $2.41B. ARGX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ARGX has Performed in-line its overall industry.
Next quarter’s sales forecast for ARGX is $1.32B with a range of $1.15B to $1.38B. The previous quarter’s sales results were $2.41B. ARGX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ARGX has Performed in-line its overall industry.

ARGX Stock Forecast FAQ

What is ARGX’s average 12-month price target, according to analysts?
Based on analyst ratings, Argenx Se’s 12-month average price target is 1,038.75.
    What is ARGX’s upside potential, based on the analysts’ average price target?
    Argenx Se has 22.34% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ARGX a Buy, Sell or Hold?
          Argenx Se has a consensus rating of Strong Buy which is based on 17 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Argenx Se’s price target?
            The average price target for Argenx Se is 1,038.75. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $1,247.00 ,the lowest forecast is $850.00. The average price target represents 22.34% Increase from the current price of $849.04.
              What do analysts say about Argenx Se?
              Argenx Se’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.
                How can I buy shares of ARGX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.